血液系统恶性肿瘤中的初级抗真菌预防:欧洲白血病感染会议(ECIL)更新的临床实践指南
欧洲白血病感染会议(ECIL)第10次会议更新了儿童和成人血液系统恶性肿瘤(HM)患者的抗真菌预防指南。针对急性髓系白血病(AML)和骨髓增生异常综合征(MDS)诱导化疗患者,艾沙康唑、米卡芬净和卡泊芬净获B-II级推荐;高危MDS接受阿扎胞苷治疗前四个周期可支持泊沙康唑预防;CAR-T细胞治疗高危患者推荐抗霉菌预防,低危患者可推荐抗酵母菌预防(B-II);儿童患者卡泊芬净获B-I级推荐。
要点
- AML/MDS诱导化疗患者:艾沙康唑、米卡芬净、卡泊芬净预防获B-II级推荐。
- 高危MDS接受阿扎胞苷治疗:前四个周期可支持泊沙康唑预防。
- CAR-T治疗:高危患者推荐抗霉菌预防,低危患者可推荐抗酵母菌预防(B-II)。
核心结论
- ECIL更新了血液系统恶性肿瘤患者的抗真菌预防指南,对AML/MDS诱导化疗、高危MDS、CAR-T治疗及儿童患者等给出了分级推荐。
- 对MPN、ALL、HL、CLL、NHL、MM及自体HSCT患者不推荐常规抗真菌预防。
研究设计与样本
- 欧洲白血病感染会议(ECIL)第10次会议制定,基于文献综述和专家小组讨论更新儿童和成人血液系统恶性肿瘤患者的抗真菌预防指南。
主要发现
- AML/MDS诱导化疗患者:艾沙康唑、米卡芬净和卡泊芬净基于非随机研究显示预防侵袭性真菌病(IFD)有效,获B-II级推荐。
- 高危MDS接受阿扎胞苷治疗:文献支持前四个周期泊沙康唑预防。
- 异基因HSCT:除植入后 period 新增艾沙康唑B-II级推荐外,无实质性变化。
- CAR-T细胞治疗:专家小组建议高危患者输注前后抗霉菌预防,低危患者可推荐抗酵母菌预防(B-II)。
- 儿童患者:卡泊芬净基于新发表数据获B-I级推荐用于抗霉菌预防;诱导治疗反应不足的ALL患儿及12岁以上儿童被视为IFD高危,推荐接受抗真菌预防。
关键数值与推荐
- AML/MDS诱导化疗:艾沙康唑、米卡芬净、卡泊芬净预防推荐等级B-II。
- 高危MDS接受阿扎胞苷:前四个周期泊沙康唑预防获文献支持。
- 异基因HSCT植入后:艾沙康唑预防推荐等级B-II。
- CAR-T治疗:高危患者抗霉菌预防;低危患者抗酵母菌预防推荐等级B-II。
- 儿童患者:卡泊芬净抗霉菌预防推荐等级B-I。
临床怎么用
- 对接受诱导化疗的AML/MDS患者可考虑艾沙康唑、米卡芬净或卡泊芬净预防(B-II)。
- 高危MDS接受阿扎胞苷治疗的前四个周期可考虑泊沙康唑预防。
- 异基因HSCT植入后 period 可考虑艾沙康唑预防(B-II)。
- CAR-T治疗高危患者推荐抗霉菌预防,低危患者可推荐抗酵母菌预防(B-II)。
- 儿童血液病患者卡泊芬净获B-I级推荐用于抗霉菌预防;诱导反应不足的ALL患儿及12岁以上儿童推荐抗真菌预防。
局限性
- AML/MDS诱导化疗中艾沙康唑、米卡芬净和卡泊芬净的B-II级推荐基于非随机研究。
- MM患者接受双特异性抗体治疗的流行病学数据有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
At the 10th European Conference on Infections in Leukaemia (ECIL), the guidelines for antifungal prophylaxis in pediatric and adult patients with hematological malignancies (HM) were updated and some changes introduced. Regarding acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) patients undergoing remission induction chemotherapy, a B-II grading has been assigned to isavuconazole, micafungin, and caspofungin, based on non-randomized studies that have shown efficacy in preventing invasive fungal diseases (IFD). Regarding high-risk MDS patients treated with azacytidine, prophylaxis with posaconazole during the first four cycles of treatment is supported in the literature. Prophylaxis is not indicated in patients treated for myeloproliferative neoplasms (NPM), acute lymphoid leukemia (ALL), and Hodgkin lymphoma (HL). For patients with chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL), prophylaxis is not generally indicated. For patients with multiple myeloma (MM), prophylaxis is not indicated and the limited epidemiological data available do not support the use of prophylaxis in subjects treated with bispecific antibodies. For patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT), no substantial changes were made, apart from the addition of isavuconazole with grading B-II in the post-engraftment period. In patients undergoing auto-HSCT, antifungal prophylaxis is not indicated. Previous ECIL guidelines did not include CAR-T cells. The expert panel proposes to endorse the use of anti-mold prophylaxis in high-risk patients during pre-infusion and post-infusion, while in low-risk patients, anti-yeast prophylaxis can be recommended (B-II). For pediatric hematology patients, based on newly published data, caspofungin received a B-I grading as mold-active prophylaxis. Moreover, patients with ALL with insufficient treatment response during induction therapy, and children older than 12 y.o are now considered at high risk for IFD and are recommended to receive antifungal prophylaxis.
引用
- Pagano L, Maschmeyer G, Lamoth F, et al. Primary antifungal prophylaxis in hematological malignancies. Updated clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL). Leukemia. 2025. PMID: 40200079. doi:10.1038/s41375-025-02586-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。